Searching for unpublished trials in Cochrane reviews may not be worth the effort

Department of General Practice and Primary Health Care, Ghent University, Belgium.
Journal of clinical epidemiology (Impact Factor: 5.48). 08/2009; 62(8):838-844.e3. DOI: 10.1016/j.jclinepi.2008.09.010
Source: PubMed

ABSTRACT To assess the value of searching for unpublished data by exploring the extent to which Cochrane reviews include unpublished data and by evaluating the quality of unpublished trials.
We screened all 2,462 completed Cochrane reviews published since 2000 in the Cochrane Database of Systematic Reviews Issue 3, 2006. In a random sample (n=61) of 292 reviews, including unpublished trials, we studied all 116 references.
Unpublished trials make up 8.8% of all included trials in our sample. Thirty-eight percent of the "unpublished" trials have in fact been published. Allocation concealment was "unclear" or not adequate in 54.3% and 61.3% reported blinding. In 47.2% reported withdrawal rates were >20%. Trials that were eventually published had larger mean population sizes (P-value, 0.02). Of the reported sponsors, 87.3% were drug companies. Methodological quality and publication bias are mentioned in half of the reviews and explored in a third. Quality ratings did not have consequences for pooling, because 82.8% was included in the forest plots.
A minority of Cochrane reviews include "unpublished trials" and many of these are eventually published. Truly unpublished studies have poor or unclear methodological quality. Therefore, it may be better to invest in regular updating of reviews, rather than in extensive searching for unpublished data.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Non-specific low back pain (NSLBP) is a large and costly problem. It has a lifetime prevalence of 80% and results in high levels of healthcare cost. It is a major cause for long term sickness amongst the workforce and is associated with high levels of fear avoidance and kinesiophobia. Stabilisation (or 'core stability') exercises have been suggested to reduce symptoms of pain and disability and form an effective treatment. Despite it being the most commonly used form of physiotherapy treatment within the UK there is a lack of positive evidence to support its use. The aims of this systematic review update is to investigate the effectiveness of stabilisation exercises for the treatment of NSLBP, and compare any effectiveness to other forms of exercise. A systematic review published in 2008 was updated with a search of PubMed, CINAHL, AMED, Pedro and The Cochrane Library, October 2006 to October 2013. Two authors independently selected studies, and two authors independently extracted the data. Methodological quality was evaluated using the PEDro scale. Meta-analysis was carried out when appropriate. 29 studies were included: 22 studies (n = 2,258) provided post treatment effect on pain and 24 studies (n = 2,359) provided post treatment effect on disability. Pain and disability scores were transformed to a 0 to 100 scale. Meta-analysis showed significant benefit for stabilisation exercises versus any alternative treatment or control for long term pain and disability with mean difference of -6.39 (95% CI -10.14 to -2.65) and -3.92 (95% CI -7.25 to -0.59) respectively. The difference between groups was clinically insignificant. When compared with alternative forms of exercise, there was no statistical or clinically significant difference. Mean difference for pain was -3.06 (95% CI -6.74 to 0.63) and disability -1.89 (95% CI -5.10 to 1.33). There is strong evidence stabilisation exercises are not more effective than any other form of active exercise in the long term. The low levels of heterogeneity and large number of high methodological quality of available studies, at long term follow-up, strengthen our current findings, and further research is unlikely to considerably alter this conclusion.
    BMC Musculoskeletal Disorders 12/2014; 15(1):416. DOI:10.1186/1471-2474-15-416 · 1.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We comprehensively reviewed published literature to determine whether it supported the link between corrected QT (QTc) interval prolongation and torsade de pointes (TdP) for the 11 second-generation antipsychotics and seven second-generation antidepressants commonly implicated in these complications. Using PubMed and EMBASE, we identified four thorough QT studies (one each for iloperidone, ziprasidone, citalopram, and escitalopram), 40 studies specifically designed to assess QTc interval prolongation or TdP, 58 publications based on data from efficacy and safety trials, 18 toxicology studies, and 102 case reports. Thorough QT studies, QTc prolongation-specific studies, and studies based on efficacy and safety trials did not link drug-associated QTc interval prolongation with TdP. They only showed that the drugs reviewed caused varying degrees of QTc interval prolongation, and even that information was not clear and consistent enough to stratify individual drugs for this risk. The few toxicology studies provided valuable information but their findings are pertinent only to situations of drug overdose. Case reports were most informative about the drug-QTc interval prolongation-TdP link. At least one additional well established risk factor for QTc prolongation was present in 92.2 % of case reports. Of the 28 cases of TdP, six (21.4 %) experienced it with QTc interval <500 ms; 75 % of TdP cases occurred at therapeutic doses. There is little evidence that drug-associated QTc interval prolongation by itself is sufficient to predict TdP. Future research needs to improve its precision and broaden its scope to better understand the factors that facilitate or attenuate progression of drug-associated QTc interval prolongation to TdP.
    CNS Drugs 08/2014; 28(10). DOI:10.1007/s40263-014-0196-9 · 4.38 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Depression is a major public health problem among adults with arthritis and other rheumatic disease. The purpose of this study was to conduct a systematic review of previous meta-analyses addressing the effects of exercise (aerobic, strength or both) on depressive symptoms in adults with osteoarthritis, rheumatoid arthritis, fibromyalgia and systemic lupus erythematous. Previous meta-analyses of randomized controlled trials were included by searching nine electronic databases and cross-referencing. Methodological quality was assessed using the Assessment of Multiple Systematic Reviews (AMSTAR) Instrument. Random-effects models that included the standardized mean difference (SMD) and 95% confidence intervals (CIs) were reported. The alpha value for statistical significance was set at p <= 0.05. The U3 index, number needed to treat (NNT) and number of US people who could benefit were also calculated. Of the 95 citations initially identified, two aggregate data meta-analyses representing 6 and 19 effect sizes in as many as 870 fibromyalgia participants were included. Methodological quality was 91% and 82%, respectively. Exercise minus control group reductions in depressive symptoms were found for both meta-analyses (SMD, -0.61, 95% CI, -0.99 to -0.23, p = 0.002; SMD, -0.32, 95% CI, -0.53 to -0.12, p = 0.002). Percentile improvements (U3) were equivalent to 22.9 and 12.6. The number needed to treat was 6 and 9 with an estimated 0.83 and 0.56 million US people with fibromyalgia potentially benefitting. Exercise improves depressive symptoms in adults with fibromyalgia. However, a need exists for additional meta-analytic work on this topic.
    BMC Musculoskeletal Disorders 04/2014; 15(1):121. DOI:10.1186/1471-2474-15-121 · 1.90 Impact Factor

Full-text (2 Sources)

Available from
Jun 5, 2014